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Abstract: Background: Central nervous system involvement is uncommon in patients with sarcoidosis. It remains a diagnostic challenge for clinicians, as there is a broad differential diagnosis that
matches the presenting neurological signs. Often, the imaging findings also overlap with other
disease entities. One understudied finding in patients with neurosarcoidosis is the presence of
medullary vein engorgement on SWI imaging, termed the “medullary vein sign”, which has been
postulated to be a specific sign for neurosarcoidosis. This study aims to provide an understanding of
the diagnostic potential of the medullary vein sign. Methods: Thirty-two patients who presented
with neurologic signs concerning for possible neurosarcoidosis were analyzed retrospectively for
the presence of the medullary vein sign. Results: Out of these cases, 7 cases of definitive neurosarcoidosis cases were found based on other imaging signs, biopsy and CSF analysis; the remaining
were classified into groups as possible (16), probable (5) and (4) cases of other infectious meningoencephalitis including 2 cases of autoimmune encephalitis. Seven patients among all of these cases
were found to have the medullary vein sign on imaging, with five cases with confirmed and two
cases from possible neurosarcoidosis. The sensitivity of the medullary vein sign in this study was
71.4%, and the specificity was 92.3%. Discussion: The benefits of improving diagnostic criteria for
neurosarcoidosis include more rapid diagnosis leading to more prompt treatment, less exposure to
potentially harmful antibiotics or antifungals, and less long-term neurological effects. Our results
support that the medullary vein sign will potentially fill in the diagnostic gaps that have challenged
the timely diagnosis of neurosarcoidosis. Conclusions: Our findings support that the medullary vein
sign has a high specificity and should be included in the diagnostic criteria for neurosarcoidosis.
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1. Introduction
Sarcoidosis is a relatively rare disease that affects more than 150,000 Americans. It is
characterized by a cell-mediated granulomatous response to unidentified antigens, which
results in the disruption of normal tissue microarchitecture [1,2]. Diagnosis is achieved
via biopsy of affected tissue, showing noncaseating granulomas, usually lung or skin.
Granulomatous inflammation in sarcoidosis can affect any organ system, most commonly
the lungs, but also the nervous system [1,3].
Neurosarcoidosis affects 3–10% of individuals with sarcoidosis, and 75% of this subset
will develop neurological symptoms within the first two years of being diagnosed with
sarcoidosis. However, up to 80% of patients with neurosarcoidosis will present with
neurological symptoms prior to the diagnosis of sarcoidosis [4–6]. Neurosarcoidosis can
affect any part of the central nervous system; however, the most common presentation is
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cranial neuropathy. Other neurological structures involved include the meninges, brain
parenchyma, neuroendocrine glands, spinal cord, and peripheral nerves [6,7].
Diagnosis is a pervasive clinical challenge in the management of neurosarcoidosis.
Diagnosing neurosarcoidosis relies on clinical signs, imaging, and CSF analysis. Historically,
the diagnosis is made clinically with proposed diagnostic criteria that varies between
physicians and institutions. Diagnostic criteria variability thus leads to a lack of specificity
and sensitivity depending on physician or institutional preferences. Current proposed
diagnostic criteria place a patient in three risk categories for neurosarcoidosis: possible,
probable, and definite. However, variability exists between diagnosticians in each of these
categories [6,7].
The imaging of choice for neurosarcoidosis work up is MRI with gadolinium, with
pathology of neurosarcoidosis affecting the brain parenchyma, leptomeninges, dura mater,
or spinal cord. The most common imaging finding in neurosarcoidosis is multiple nonenhancing periventricular white matter lesions. The most specific is the “trident sign,” in
the dorsal cord region, which is thought to relate to perivascular spread of leptomeningeal
granulomatous inflammation [5,8,9]. Cerebrospinal fluid (CSF) analysis is also non-specific,
although elevated levels of angiotensin converting enzyme (ACE) in the CSF is common in
neurosarcoidosis. However, the false-positive and false-negative rate is high. Only 33–50%
of patients with elevated CSF ACE have neurosarcoidosis according to the literature [8,10].
The differential based on the above diagnostic findings is thus quite broad and includes
Neurosarcoidosis, CNS lymphoma, multiple sclerosis, infectious disease, autoimmune
disease, osmotic demyelination, and other demyelinating diseases [10].
Treating neurosarcoidosis involves first-line intravenous corticosteroids in an effort
to reduce granulomatous inflammation within the nervous system, just as sarcoidosis
would be treated outside the nervous system. Second-line treatments include methotrexate,
azathioprine, mycophenolate mofetil, and chloroquine [3,10]. A favorable outcome was
reported in 71% of patients receiving corticosteroid monotherapy. In a meta-analysis
performed by Fritz et al., 27% of patients reached remission, 32% achieved incomplete
remission, 24% had stable pathology, and 6% deteriorated. The delay in treatment initiation
may have significant implications on disease progression and chances of remission [11].
Further updates on treatment guidelines were recently revised by the European Respiratory
Society in 2021 [12].
The literature for neuroimaging findings specific to neurosarcoidosis is relatively
scarce. An association between existing neurosarcoidosis and medullary vein engorgement
has only been cited once, but the imaging finding itself is uncommon to other pathology
outside of medullary vein thrombosis, dural AV fistula, and rarely systemic lupus erythematosus [9,11]. The only case series on this topic cites 33% (7 of 21) of patients with
neurosarcoidosis to demonstrate medullary vein engorgement on susceptibility weighted
magnetic resonance imaging (SWI) [7]. In patients with isolated neurologic symptoms, this
imaging finding can be important in contributing to the more efficient diagnosis of neurosarcoidosis in the presence of supporting signs. This study aims to provide the relevance
of potential of the medullary vein sign in neuroimaging marker in neurosarcoidosis.
2. Materials and Methods
A single center retrospective study of patients recruited at the Department of Neurology, West Virginia University (WVU) was performed between 1 August 2022 and 31 March
2022. We have included 7 definitive neurosarcoidosis cases in this study from amongst a
total of 32 patients based on inclusion criteria of confirmed diagnosis of neurosarcoidosis.
Among them, 7 of these cases had the characteristic medullary vein sign on SWI/GRE
sequences on MRI brain imaging (Figure 1). Data analysis included age, sex, symptoms,
risk factors, serology status for antibodies, imaging findings, treatment, and recovery
(Table 1). Two neuroradiologists independently performed the neuroimaging study. Neuroimaging findings and pathophysiology comparisons that were considered within the
scope of our study were mainly focused on medullary vein signs and leptomeningeal and
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pachymeningeal enhancement (Figures 1 and S1). In this study, MRI images were reviewed
using SWI/GRE sequences in a retrospective search for medullary vein engorgement,
termed medullary vein sign. Of the total 32 patients reviewed, 7 were confirmed to have
neurosarcoidosis through biopsy and diagnosis of exclusion. Sensitivity was calculated
as the number of correctly identified cases of neurosarcoidosis based on medullary vein
sign divided by the total number of patients in this study that were found to have confirmed neurosarcoidosis. Specificity was calculated as the number of patients in the study
who did not have neurosarcoidosis or the medullary vein sign divided by all individuals
without neurosarcoidosis.

Figure 1. MRI axial (a) of the gadolinium-enhanced
brain demonstrating perivascular enhancement throughout (red arrow); MR
Figure 1. MRI axial (a) of the gadolinium-enhanced brain demonstrating perivascular enhancement
mages (SWI) show mildly dilated medullary
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perpendicular
to long suspected
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arrowhead);
throughout (red arrow);
MRI brain (b,d,f,h)
weightventricles
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(g) axial cuts in post-gadolinium-enhanced MRI of the brain show leptomeningeal enhancement (red
arrowhead) and pachymenigeal enhancement (red arrow).
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Table 1. MRI Imaging and image analysis findings. The table lists five cases of confirmed neurosarcoidosis with a positive medullary vein sign upon review of MRI
imaging along with clinical presentation, MRI findings, CSF analysis, treatment, and clinical outcome.
Case

1*

2*

3*

4*

Age/Gender

56 y.o Female

34 y.o. female

62 y.o. Female

32 y.o. female

Year of Diagnosis

Onset/Presentation

CSF Analysis

MRI Results

Treatment

Outcomes

2015

Confusion, thought
blocking,
leg weakness

WBC: 50
70% lymphocytes; 30%
mononuclear
Protein: 57 mg/dL

Small focus of restricted
diffusion along left
lateral medulla
Medullary vein sign +

Outpatient follow-up
Risk factor reduction

Resolution of
acute confusion
Residual facial numbness
and leg weakness
No progression

CSF ACE: normal
Serum ACE: 137 U/L
Glucose: 44 mg/dL
WBC: 10
Lymphocytes: 79%
PMNs: 10%
Monos: 7%

Nonspecific markedly
abnormal appearance of
nodular enhancement
and thickening along the
pial surface in posterior
fossa and basal cisterns
and along tentorium and
interhemispheric fissure.
Developing
hydrocephalus
Medullary Vein sign +

IV solumedrol 1 g for
3 days
Followed by 40 mg
prednisone PO
Methotrexate 10 mg
weekly
VP Shunt

No show to several appts.
Headaches/vomiting
unresolved but vision
problems improved

2015

Double vision, facial
paresthesia,
proprioception/balance deficits

CSF ACE: normal
CSF Glucose: 59 mg/dL
Protein: 41 mg/dL
WBC: 5

Diffuses dural thickening
with marked dural
enhancement in
parasellar region
Medullary vein sign +
Mild leptomeningeal
enhancement of
optic nerves

1000 solumedrol for four
days, followed by PO
steroid 60 mg for
one month
Methotrexate
Rituximab Q6 months

Continued headaches after
cessation of steroids. Visual
problems after cessation of
steroids. Was restarted on a
steroid taper.
Subsequently weaned off
steroids and started on
Methotrexate in 2017, which
improved headaches and
visual symptoms

2018

Intermittent
monocular blindness
and blurry vision
Headache
Vertigo
N/V
Numbness

CSF protein: 66 mg/dL
CSF Glucose: 54 mg/dL
WBC: 6
35% neutrophil
48% lymphs

Scattered nonenhancing
parenchymal lesions in
white matter of cerebral
hemispheres
Medullary vein sign +

1 g Solumedrol IV TI,
transitioned to PO
prednisone taper
1 dose IV methotrexate
transitioned to 25 mg
oral once per 1 week

Improvement in N/V,
headaches, and vertigo. Still
some residual vision
impairment treated with
subcutaneous methotrexate
per her ophthalmologist

2013

Intractable headache
Weakness
Nausea/Vomiting
Vision change
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Table 1. Cont.
Case

5*

6 **

7 **

Age/Gender

33 y.o. Female

27/y o
Female

48/yo
Male

Year of Diagnosis

2018

2019

2018

Onset/Presentation

CSF Analysis

MRI Results

Treatment

Outcomes

Papilledema
Neck pain
New blurry vision
headaches

Protein: 216 mg/dL
Glucose: 38 mg/dL
WBC: 7
neutrophil % 1
Lymphocyte % 70
Monocytes % 27
ACE CSF: 3.5

Scattered bilateral
cerebral white matter
lesions, some with
associated enhancement.
Leptomeningeal
enhancement
Medullary Vein sign +

Prednisone taper
transition to imuran

Complete resolution
of symptoms

None

Multiple ring-enhancing
lesions on post contrast
T1 images, the largest
within the right basal
ganglia and the pons

1 g Solumedrol IV TI,
transitioned to PO
prednisone taper

stable

CSF ACE mildly
elevated at 3.7 U/L
(normal up to 2.5),
12 WBC predominant
lymphocytic 90%, and
negative
meningitis panel

Enhancing left cerebellar
nodule with surrounding
abnormal hyperintense
signal on FLAIR
extending to the
cerebellar peduncle.
Mass-like enhancement
of the folia surrounding
the nodule was also
noted. MRI orbits
showed bilateral smooth
optic nerve sheath
enhancement without
abnormal signal within
the optic nerves

on 1 dose of
cyclophosphamide with
Mesna and discharged
with oral tapering
prednisone

Partial improvement
in vision

Left upper and lower
extremity weakness

of bilateral
retro-orbital pain and
progressive vision
loss over the course
of two months

* Definitive neurosarcoidosis; ** Possible neurosarcoidosis; ACE, Angiotensin-converting enzymes; PMN, Polymorphonuclear neutrophil.
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3. Results
3.1. General Results
Among the 32 patient charts reviewed at WVU, a total of 7 were classified as definite
neurosarcoidosis based on tissue biopsy with (including three cases of cervical spine
biopsy proven sarcoidosis) additional diagnostic labs including CSF and MRI imaging,
16 were possible neurosarcoidosis based on CSF and MRI findings, and 5 were probable
neurosarcoidosis based on extra neuronal tissue biopsy (hilar lymphadenopathy biopsy
with lung sarcoidosis, skin and bone biopsy). Among the 32 patients, 4 were found to have
a different etiology for neurological symptoms other than neurosarcoidosis (1 bacterial
menigoencephalitis;1 fungal encephalitis; 2 CNS autoimmune encephalitis). In 28 out of
32 possible/definitive neurosarcoidosis cases, 17 were female, and 11 were male. The most
common symptoms involved in the patients with definite/possible neurosarcoidosis were
progressive vision changes, limb weakness, and headache. The average age of presenting
symptoms was 55 years old, spanning from 27 to 83 years old. The most common treatments
were intravenous methylprednisone followed by prednisone taper (25%), methotrexate
and rituximab (12%), with few patients receiving azathioprine (1%); treatment information
for the rest of the cases was not available. There were no fatal cases reported, and patients
were stable following treatment of the presenting symptoms. Ten patients presenting
with symptoms of neurosarcoidosis had a prior diagnosis of tissue biopsy of either lung
sarcoidosis or non-caseating granuloma of skin or bone.
The sensitivity of the medullary vein sign in this study was 71.4% and the specificity
was 92.3% among patients with either a definite diagnosis or definite rule out of neurosarcoidosis (total of 32 patients). The sensitivity of the medullary vein sign in all reviewed
patients including those with suspected but not confirmed (counting as a positive case of
neurosarcoidosis), and definite neurosarcoidosis, and the number of patients who were
found not to have neurosarcoidosis was lower at 25% (total of 28/32 patients).
3.2. CSF Findings
Patients with possible, probable or definite neurosarcoidosis had mostly inconclusive
CSF findings except for three patients who had elevated CSF ACE levels. Total cell counts
were mildly elevated in 13 of 32 cases with predominant lymphocytosis. Ten cases had
elevated protein levels of >50 mg/dL. Patients without diagnosis of neurosarcoidosis who
had neurologic symptoms due to another etiology had elevated cell counts in CSF including
lymphocytes >80% or neutrophil counts greater than 75% (four cases).
3.3. MRI Findings
MRI findings in patients with possible or definite neurosarcoidosis were mostly leptomeningeal enhancement, cord lesions, or scattered parenchymal lesions. On chart review,
MRI findings were not a deciding factor in diagnosis in many cases. MRI findings consistent with possible neurosarcoidosis led to brain biopsy in only three cases, all of which
confirmed neurosarcoidosis. Seven total cases had medullary vein engorgement upon
retrospective image analysis as part of this study.
4. Discussion
Sarcoidosis has been shown to manifest itself in the nervous system in about 3–10% of
patients with systemic sarcoidosis [1]. Difficulties in the diagnosis are largely attributed
to debates in proper diagnostic criteria. The presenting symptoms of neurosarcoidosis
are similar to several other pathologies such as fungal, bacterial or viral meningitis, other
autoimmune diseases, or demyelinating diseases. These issues raise a concern for delayed
diagnosis and treatment initiation and necessitate other means of differentiating between
neurosarcoidosis and other pathologies, especially in individuals who have not had a prior
diagnosis of sarcoidosis in other organ systems [13–19].
Susceptibility weighted imaging (SWI) is a largely accessible neuroimaging tool that
has shown characteristic results in patients with neurosarcoidosis. Deep medullary vein
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engorgement has been associated with neurosarcoidosis as well as other autoimmune
diseases such as systemic lupus erythematosus [14,20–23]. This finding is hypothesized to
be caused by a chronic inflammatory reaction. Over time, this immune response causes
microvascular damage, which can be seen as localized white matter injury and vessel
dilation [21]. To date, there has not been sufficient research on the utility of SWI imaging
related to diagnosing diseases such as neurosarcoidosis.
SWI imaging has also been recognized as a sensitive and specific test for brain venous malformations [20,24]. This pathology is visualized on SWI as hyperintensities [25].
However, the clinical picture is much different in neurosarcoidosis and brain venous malformation. Venous malformations present with headache and continue to progress as bleeding
continues [20].
Deep medullary veins are easily visualized on SWI as hypointense linear structures perpendicular to the lateral ventricles. As seen in this study, as well as other studies, medullary
vein engorgement will present as enlarged, tortuous veins that are usually symmetric and
near the level of the corona radiata [19,21]. A previous study by Zamora et al. [19] also
demonstrated the finding of deep medullary vein engorgement in patients with neurosarcoidosis and further found that these patients were more likely to have perivascular space
involvement. This finding may support the pathogenesis of sarcoidosis spread to the CNS,
which is thought to occur through hematogenous spread with eventual dissemination into
the perivascular spaces [16].
Though the sensitivity is relatively low, the medullary vein sign should be used as
an adjunct to other previously described criteria for neurosarcoidosis as mentioned above.
Rather than being used as a diagnostic criterion alone, it is best to use this finding as
an adjunct in supporting the diagnosis of neurosarcoidosis. It should be used to inform
radiologists to actively look for this sign when neurosarcoidosis is being considered in the
differential diagnosis. It is worth reiterating that none of the patients who were retrospectively found to have signs supportive of medullary vein engorgement had any mention of
this findings in the initial MRI dictation. This supports the idea that revised guidelines for
the diagnosis and treatment of neurosarcoidosis should include a review of SWI/GRE sequences to assess for the presence of the medullary vein sign. The presence of the medullary
vein sign should be added to the previously studied MRI findings in neurosarcoidosis
such as leptomeningeal enhancement, hydrocephalus, and parenchymal lesions that are
sensitive but not specific to neurosarcoidosis [15,22,23]. In our study, the specificity of
medullary vein engorgement is 92.3% filling in a diagnostic gap in the investigation of
possible neurosarcoidosis. Therefore, in patients with suspected neurosarcoidosis, SWI
imaging, which is more sensitive than GRE, should be utilized in the search for a medullary
vein sign.
As mentioned previously, the differential diagnosis in patients with neurological signs
concerning for neurosarcoidosis includes fungal, viral, and bacterial infections [17,18]. Six
of the ten patients with confirmed neurosarcoidosis were initially treated with antibiotics
or antifungals due to erroneous diagnosis of infection. These patients retrospectively had
confirmed medullary vein signs on imaging. In these cases, SWI imaging demonstrating the
medullary vein sign would have potentially prevented the unnecessary use of antibiotics
and antifungals. The earlier diagnosis of neurosarcoidosis would also expedite the time to
initiation of systemic corticosteroid treatments.
Many patients with neurosarcoidosis have already initiated treatment for sarcoidosis
before they present with neurologic symptoms, which renders MRI less sensitive, as the
classic imaging findings of neurosarcoidosis may be resolving or resolved. SWI provides
a unique utility for the efficient diagnosis of NS [1,5,22]. This study demonstrates that
SWI is a useful tool for early diagnosis of neurosarcoidosis and expedited treatment. More
information is still needed to determine if deep vein engorgement findings on SWI are
indicative of prognostic factors as well as specificity for neurosarcoidosis.
In the future, SWI may be useful in monitoring patients’ disease progression preand post-treatment. More research will need to be conducted to better demonstrate the
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sensitivity and specificity of SWI in diagnosing neurosarcoidosis, but this case series
presents supporting evidence of the utility of the medullary vein sign on SWI sequence.
The results of this study should prompt health care professionals to consider using this
sign to aid in the diagnosis of neurosarcoidosis in the appropriate clinical setting.
CSF analysis in all confirmed cases of neurosarcoidosis was largely an unimportant
part of the diagnosis. CSF ACE was elevated in three out of ten confirmed neurosarcoidosis cases.
Limitations to this study are mostly due to the small number of patients we were able
to find with confirmed neurosarcoidosis. The sensitivity and specificity calculated in this
study are thus likely not a true measure of the diagnostic potential of the medullary vein
sign in SWI sequence for neurosarcoidosis. It is likely that the sensitivity of the medullary
vein sign would remain low; however, the specificity of this imaging finding is likely even
higher. Other limitations to the study are due to the retrospective nature of the study. The
neuroradiologist reviewed images back in time to assess for a specific sign in patients who
were already known to have neurosarcoidosis, causing potential recall bias. Though this is
a drawback to the study, the lack of literature on this topic prevents a prospective study
from being performed in an efficient manner. More research is necessary to confirm the
diagnostic value of the medullary vein sign. This study supports the use of the medullary
vein sign on SWI imaging sequences as part of the criteria in diagnosing neurosarcoidosis
in patients with and without other organ involvement of sarcoidosis.
Supplementary Materials: The following supporting information can be downloaded at: https://
www.mdpi.com/article/10.3390/neurolint14030052/s1, Figure S1. MRI axial T1 images 1(a) of the
gadolinium-enhanced brain demonstrating dural thickening and enhancement of the right tentorium
and cerebellopontine angle (blue and red arrow).
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List of Abbreviation
MRI
CSF
EVD
ACE
LP
TTE
ICP
CNS
NMO
MS

Magnetic Resonance Imaging
Cerebrospinal fluid
External Ventricular drain
Angiotensin converting enzymes
Lumbar Puncture
Transthoracic Echocardiography
Intracranial Pressure
Central Nervous System
Neuromyelitis Optica
Multiple Sclerosis
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CN
SWI
MRI
OSA
GERD
IVDU
SE
MP-RAGE
MIP
MinIP

Cranial Nerve
Susceptibility weighted imaging
Magnetic resonance imaging)
obstructive Sleep apnea
Gastroesophageal reflux disease
Intravenous drug use
spin-echo
magnetization prepared rapid gradient echo
maximum intensity projection
minimum intensity projection
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